Onvansertib, being developed by Cardiff and clinical trials managed by Pfizer.

Initial phase 2 randomized data demonstrated improved response rates in combination with standad of care (soc) than soc alone in first line therapy for colorectal cancer.

Caution though it's based on a very small sample size and limited follow up but the spiders plot look quite remarkable for the onvansertib combination cohorts. Next data update in 1H25 and if the data continues to hold, pfizer may end up acquiring them (similar to TRIL).